Articles by Daniel Marsh
ServiceNow Holds Near $100 as AI Spending Scrutiny Weighs on Software Sector
ServiceNow shares steadied near $100 following a sharp sell-off, as market pressure mounts on software firms to demonstrate returns from heavy AI investments. All eyes turn to Friday's inflation report for direction.
Bloom Energy Shares Slide 9% Amid AI Spending Doubts, CPI Wait
Bloom Energy shares dropped 9.2% Thursday, reversing early gains as tech stocks retreated. Investors weighed the company's $6 billion backlog against uncertainty over AI infrastructure spending and Federal Reserve policy.
Adobe Stock Slides Amid AI Uncertainty and Rate Concerns
Adobe stock declined 1.4% to $253.66, tracking broader software sector weakness. Investors are weighing AI disruption risks against monetary policy uncertainty.
Verizon Shares Reach 52-Week Peak Amid Telecom Sector Strength
Verizon Communications shares surged to a fresh 52-week high, approaching $50, as telecom stocks rallied against a declining S&P 500. The advance follows the company's robust free cash flow outlook and a multi-billion dollar share repurchase authorization.
Goldman Sachs Shares Slide 3.8% Amid Sector-Wide Retreat Ahead of CPI
Goldman Sachs shares dropped 3.8% to $908.84 Thursday, mirroring a broad decline in financial stocks as markets await Friday's crucial inflation report.
FTSE 100 Retreats from Record High on Weak UK Growth Data
The FTSE 100 closed lower after touching a record intraday high, pressured by disappointing UK economic figures. Schroders shares soared following a major takeover offer from US asset manager Nuveen.
Mortgage Rates Hold Near 6% as Housing Data Dampens Sentiment
Mortgage rates held steady above 6% this week as the housing market shows signs of strain, with existing-home sales declining sharply. Rocket Companies shares fell amid the cautious sentiment.
Lilly Gains on China IBD Drug Approval, Oral GLP-1 Race Heats Up
Eli Lilly shares advanced nearly 2% after securing Chinese approval for its inflammatory bowel disease drug mirikizumab. Investors also await a key U.S. decision on the company's oral weight-loss pill expected in April.
Caterpillar Gains as Argus Boosts Target to $820, Insider Sale Notice Filed
Caterpillar shares advanced 0.6% following a prior surge after Argus Research raised its price target to $820. An insider filed to potentially sell shares worth approximately $9.6 million.